{"id":799418,"date":"2025-01-10T06:33:19","date_gmt":"2025-01-10T11:33:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/"},"modified":"2025-01-10T06:33:19","modified_gmt":"2025-01-10T11:33:19","slug":"intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/","title":{"rendered":"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0"},"content":{"rendered":"
\n

BEDMINSTER,\u00a0N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc.\u00a0(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into\u00a0a settlement agreement\u00a0with\u00a0Sandoz\u00a0Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies\u2019 product\u00a0CAPLYTA\u00ae (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jersey, resulted from submission by\u00a0Sandoz\u00a0of an Abbreviated New Drug Application\u00a0to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of CAPLYTA in the United States. The settlement agreement\u00a0permits\u00a0Sandoz\u00a0to begin selling generic versions of CAPLYTA on July 1, 2040, or earlier under certain circumstances. As required by law, Intra-Cellular Therapies will submit the agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice. Similar patent litigation brought by Intra-Cellular Therapies against other parties remains pending in the U.S. District Court for the District of New Jersey.\u00a0<\/p>\n

\n About\u00a0Intra-Cellular Therapies<\/strong>\n <\/p>\n

Intra-Cellular Therapies\u00a0is a biopharmaceutical company founded\u00a0on\u00a0Nobel\u00a0prize-winning\u00a0research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit\u00a0www.intracellulartherapies.com<\/a><\/u>.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333<\/p>\n

Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com<\/a><\/u>
646-930-4406<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BEDMINSTER,\u00a0N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc.\u00a0(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into\u00a0a settlement agreement\u00a0with\u00a0Sandoz\u00a0Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies\u2019 product\u00a0CAPLYTA\u00ae (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jersey, resulted from submission by\u00a0Sandoz\u00a0of an Abbreviated New Drug Application\u00a0to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of CAPLYTA in the United States. The settlement agreement\u00a0permits\u00a0Sandoz\u00a0to begin selling generic versions of CAPLYTA on July 1, 2040, or earlier under certain circumstances. As required by law, Intra-Cellular Therapies will submit the agreement to … <\/p>\n

Continue reading “Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0“<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-799418","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIntra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDMINSTER,\u00a0N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc.\u00a0(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into\u00a0a settlement agreement\u00a0with\u00a0Sandoz\u00a0Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies\u2019 product\u00a0CAPLYTA\u00ae (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jersey, resulted from submission by\u00a0Sandoz\u00a0of an Abbreviated New Drug Application\u00a0to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of CAPLYTA in the United States. The settlement agreement\u00a0permits\u00a0Sandoz\u00a0to begin selling generic versions of CAPLYTA on July 1, 2040, or earlier under certain circumstances. As required by law, Intra-Cellular Therapies will submit the agreement to … Continue reading "Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T11:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0\",\"datePublished\":\"2025-01-10T11:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/\",\"name\":\"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=\",\"datePublished\":\"2025-01-10T11:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/","og_locale":"en_US","og_type":"article","og_title":"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0 - Market Newsdesk","og_description":"BEDMINSTER,\u00a0N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc.\u00a0(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into\u00a0a settlement agreement\u00a0with\u00a0Sandoz\u00a0Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies\u2019 product\u00a0CAPLYTA\u00ae (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jersey, resulted from submission by\u00a0Sandoz\u00a0of an Abbreviated New Drug Application\u00a0to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of CAPLYTA in the United States. The settlement agreement\u00a0permits\u00a0Sandoz\u00a0to begin selling generic versions of CAPLYTA on July 1, 2040, or earlier under certain circumstances. As required by law, Intra-Cellular Therapies will submit the agreement to … Continue reading \"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-10T11:33:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0","datePublished":"2025-01-10T11:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/"},"wordCount":261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/","name":"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=","datePublished":"2025-01-10T11:33:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTc0OSM2Njg1Nzg1IzIwMDg4ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intra-Cellular Therapies Settles CAPLYTA\u00ae\u00a0(lumateperone)\u00a0Patent Litigation with\u00a0Sandoz\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=799418"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799418\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=799418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=799418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=799418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}